IRIS
PALA, Daniele
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.777
AS - Asia 1.488
EU - Europa 1.346
SA - Sud America 199
AF - Africa 79
OC - Oceania 1
Totale 4.890
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.729
SG - Singapore 575
CN - Cina 539
FI - Finlandia 319
IE - Irlanda 244
IT - Italia 226
SE - Svezia 208
BR - Brasile 161
DE - Germania 133
HK - Hong Kong 116
TR - Turchia 78
VN - Vietnam 74
NL - Olanda 47
ZA - Sudafrica 45
FR - Francia 35
GB - Regno Unito 34
IN - India 27
CA - Canada 24
BE - Belgio 22
CI - Costa d'Avorio 22
AR - Argentina 21
UA - Ucraina 20
MX - Messico 17
JP - Giappone 14
RU - Federazione Russa 13
BD - Bangladesh 8
ES - Italia 8
ID - Indonesia 8
IQ - Iraq 8
CZ - Repubblica Ceca 7
LT - Lituania 7
PK - Pakistan 6
JO - Giordania 5
MA - Marocco 5
PL - Polonia 5
VE - Venezuela 5
EC - Ecuador 4
AZ - Azerbaigian 3
HU - Ungheria 3
IL - Israele 3
PS - Palestinian Territory 3
PY - Paraguay 3
AE - Emirati Arabi Uniti 2
AL - Albania 2
AT - Austria 2
CL - Cile 2
CO - Colombia 2
HN - Honduras 2
KE - Kenya 2
KG - Kirghizistan 2
KR - Corea 2
LV - Lettonia 2
MD - Moldavia 2
MY - Malesia 2
NP - Nepal 2
TN - Tunisia 2
TW - Taiwan 2
AM - Armenia 1
AO - Angola 1
BG - Bulgaria 1
BH - Bahrain 1
BO - Bolivia 1
CH - Svizzera 1
CY - Cipro 1
DO - Repubblica Dominicana 1
EE - Estonia 1
EG - Egitto 1
GR - Grecia 1
GT - Guatemala 1
LK - Sri Lanka 1
NI - Nicaragua 1
NO - Norvegia 1
OM - Oman 1
PA - Panama 1
PH - Filippine 1
RO - Romania 1
SA - Arabia Saudita 1
SK - Slovacchia (Repubblica Slovacca) 1
SN - Senegal 1
SY - Repubblica araba siriana 1
TV - Tuvalu 1
UZ - Uzbekistan 1
VG - Isole Vergini Britanniche 1
Totale 4.890
Salva come PNG Salva come JPEG
Città #
Singapore 297
Dublin 244
Chandler 238
Ashburn 223
Santa Clara 147
Dallas 141
Beijing 138
Parma 131
Hong Kong 114
Dearborn 82
Izmir 71
Boardman 69
Ann Arbor 66
Nanjing 63
Shanghai 50
Johannesburg 43
Bremen 42
New York 42
Princeton 42
Los Angeles 41
Jacksonville 38
Munich 37
Wilmington 35
Helsinki 25
Hanoi 24
Ho Chi Minh City 24
Abidjan 22
Columbus 21
Brussels 20
Kunming 19
San Mateo 19
Shenyang 19
Düsseldorf 15
Hebei 15
Hefei 15
São Paulo 15
Nanchang 14
Seattle 13
Tokyo 13
Turku 13
Jinan 12
Toronto 12
Guangzhou 11
Jiaxing 11
Moscow 11
Changsha 10
Buffalo 9
Chennai 9
Hangzhou 9
London 9
Phoenix 8
Tianjin 8
Belo Horizonte 7
Boston 7
Brooklyn 7
Jakarta 7
Norwalk 7
San Jose 7
The Dalles 7
Woodbridge 7
Mexico City 6
Modena 6
Montreal 6
Pune 6
Rio de Janeiro 6
Rome 6
Stockholm 6
Amman 5
Fremont 5
Grafing 5
Milan 5
Orem 5
Poplar 5
San Francisco 5
Zhengzhou 5
Ankara 4
Atlanta 4
Borås 4
Brescia 4
Council Bluffs 4
Fuzhou 4
Haikou 4
Hyderabad 4
Ninh Bình 4
Nova Iguaçu 4
Nuremberg 4
Olomouc 4
Shijiazhuang 4
Springfield 4
Taizhou 4
Warsaw 4
Baku 3
Brasília 3
Chicago 3
Curitiba 3
Denver 3
Guarulhos 3
Houston 3
Lahore 3
Manaus 3
Totale 3.048
Salva come PNG Salva come JPEG
Nome #
Inhibition of Eph/ephrin interaction with the small molecule UniPR500 improves glucose tolerance in healthy and insulin-resistant mice 213
Dibasic biphenyl H(3) receptor antagonists: Steric tolerance for a lipophilic side chain. 188
UniPR129 is a competitive small molecule Eph-ephrin antagonist blocking in vitro angiogenesis at low micromolar concentrations. 180
Development of an orally bioavailable small molecule targeting Eph-ephrin system: in vitro and in vivo anticancer activity. 173
Combining ligand- and structure-based approaches for the discovery of new inhibitors of the EPHA2-ephrin-A1 interaction 168
Amino acid conjugates of lithocholic acid as antagonists of the EphA2 receptor. 163
Discovery and development of Eph-ephrin antagonists endowed with antiangiogenic properties 155
Design and structure-activity relationship of amino acid derivatives of lithocholic acid as novel EphA2 antagonists 149
Atropisomerism and Conformational Equilibria: Impact on PI3Kδ Inhibition of 2-((6-Amino-9H-purin-9-yl)methyl)-5-methyl-3-(o-tolyl)quinazolin-4(3H)-one (IC87114) and Its Conformationally Restricted Analogs 146
Development of 3-oxo-cholenic derivatives as Eph antagonists able to block in vitro angiogenesis 142
Multiple approaches for the discovery and development of small molecules targeting Eph-ephrin protein-protein interaction 135
270 Discovery, development and optimization of low molecular weight EPH–ephrin protein–protein inhibitors 133
Design and structure-activity relationships of amino acid derivatives of lithocholic acid as novel EphA2 receptor antagonists. 131
Toward the Definition of Stereochemical Requirements for MT(2)-Selective Antagonists and Partial Agonists by Studying 4-Phenyl-2-propionamidotetralin Derivatives. 130
Δ5-Cholenoyl-amino acids as selective and orally available antagonists of the Eph-ephrin system 130
Biochemical characterization of EphA2 antagonists with improved physico-chemical properties by cell-based assays and surface plasmon resonance analysis 129
Comparative Analysis of Virtual Screening Approaches in the Search for Novel EphA2 Receptor Antagonists 128
Discovery and development of low molecular weight Eph-ephrin protein-protein inhbi-tors endowed with antiangiogenic activity 122
Exploiting Free-Energy Minima to Design Novel EphA2 Protein-Protein Antagonists: From Simulation to Experiment and Return 121
Combining pharmacology, target hopping and computational medicinal chemistry to discover novel scaffold targeting EPH-ephrin interaction. 121
Metadynamics for perspective drug design: Computationally driven synthesis of new protein-protein interaction inhibitors targeting the EphA2 receptor 119
Target Hopping as a Useful Tool for the Identification of Novel EphA2 Protein–Protein Antagonists 115
Metadynamics Simulations Distinguish Short- and Long-Residence-Time Inhibitors of Cyclin-Dependent Kinase 8. 115
Free-energy studies reveal a possible mechanism for oxidation-dependent inhibition of MGL 112
New classes of potent heparanase inhibitors from ligand-based virtual screening 107
Complex product composition generates risks for generic substitution also with dosage forms for intravenous administration 106
Computer-Aided Design of Novel Antagonists of the EphA2 Receptor 102
Highly Potent and Selective MT2 Melatonin Receptor Full Agonists from Conformational Analysis of 1-Benzyl-2-acylaminomethyl-tetrahydroquinolines 102
Homology models of melatonin receptors: challenges and recent advances. 101
Synthesis and Structure-Activity Relationships of Amino Acid Conjugates of Cholanic Acid as Antagonists of the EphA2 Receptor. 100
Target-hopping: a useful approach to identify novel Eph receptor antagonists 97
ST7612AA1, a thioacetate-ω(γ-lactam carboxamide) derivative selected from a novel generation of oral HDAC inhibitors 95
Synthesis and characterization of new bivalent agents as melatonin- and histamine h3-ligands. 92
Synthesis of (E)-8-(3-chlorostyryl)caffeine analogs leading to 9-deazaxanthine derivatives as dual A2A antagonists /MAO-B inhibitors. 87
Recent advances in the development of melatonin MT(1) and MT(2) receptor agonists. 83
In vitro and in vivo efficacy of an orally bioavailable antagonist of Eph-ephrin system in tumor angiogenesis and growth 79
Towards the development of 5-HT7 ligands combining serotonin-like and arylpiperazine moieties 75
Structure-based virtual screening of MT2 melatonin receptor: influence of template choice and structural refinement. 71
Synthesis, structure and inhibitory activity of a stereoisomer of oseltamivir carboxylate 69
Therapeutic uses of melatonin and melatonin derivatives: a patent review (2012 - 2014) 67
MT1-Selective Melatonin Receptor Ligands: Synthesis, Pharmacological Evaluation, and Molecular Dynamics Investigation of N-[[(3-O-Substituted)anilino]alkyl]amides. 67
Kinetic analysis and molecular modeling of the inhibition mechanism of roneparstat (SST0001) on human heparanase 66
Totale 4.984
Salva come PNG Salva come JPEG
Categoria #
all - tutte 17.651
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 17.651
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021102 0 0 0 0 0 10 11 7 41 13 12 8
2021/2022184 6 2 3 28 2 7 8 25 7 14 16 66
2022/2023891 99 107 39 60 103 97 14 48 299 2 21 2
2023/2024288 16 27 4 13 21 61 36 24 8 14 24 40
2024/2025994 26 64 61 55 120 109 49 45 132 76 97 160
2025/20261.321 212 269 235 188 291 126 0 0 0 0 0 0
Totale 4.984